Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

102 results about "Vaccinia" patented technology

Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It has a linear, double-stranded DNA genome approximately 190 kbp in length, which encodes approximately 250 genes. The dimensions of the virion are roughly 360 × 270 × 250 nm, with a mass of approximately 5–10 fg.

Vaccinia virus diluting device

The invention discloses a vaccinia virus diluting device, which belongs to the technical field of diluting devices and comprises an upper mixing shell and a circular opening A formed in the middle of the top of the upper mixing shell. Through mutual cooperation of a circular seat, a spiral stirring blade, a rotating gear, an inner gear ring, a driving motor B, a hollow gear ring, a rack plate, a limiting plate, a movable rod, a belt A, a rotating disc, a sliding shaft, a rectangular frame, a U-shaped rod, a circular ring, a fixed rod and a fixed plate, the spiral stirring blade can be driven to rotate to realize stirring and mixing of vaccinia and diluent; meanwhile, spiral stirring blades can be driven to rotate and can also swing and stir back and forth in the lower mixing shell, so that the mixing efficiency is better, and a flat plate, a transmission rod, a belt B, a transmission gear, an outer gear ring and a feeding pipe are matched with one another, so that the feeding pipe can be driven to rotate on the outer side of the lower mixing shell, and the mixing efficiency is improved. Annular addition of the diluent is achieved, and the effect of mixing the diluent with vaccinia is better.
Owner:VANWORLD PHARMA (RUGAO) CO LTD

Enzymatic RNA capping method

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.
Owner:NEW ENGLAND BIOLABS INC

Epstein-barr virus vaccine

The present invention relates to vaccines based on viral vectors for delivery of antigens against infectious diseases. In particular, the present invention relates to a recombinantly modified vaccinia virus Ankara (MVA) encoding EBV antigens that elicit infectious mononuclear hyperplasia (IM) and different cancer types. The invention also relates to medical application of the recombinant MVA in prevention of diseases caused by EBV (Epstein-Barr Virus).
Owner:BAVARIAN NORDIC AS

Oncolytic virus improved in safety and anticancer effect

A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.
Owner:BIONOXX INC

Construction method and application of oncolytic vaccinia virus vector with C2L gene deletion

The invention relates to a construction method and application of a C2L gene-deleted oncolytic vaccinia virus vector, the virus vector is Lister strain vaccinia virus, a C2L gene is deleted on the basis that a J2R gene is deleted, and the vector can be inserted into any antigen gene beneficial to tumor treatment or used for vaccines for infectious diseases. Wherein the VV [delta] TK [delta] C2L has specificity, safety and high efficiency, can carry various antigen genes for treating tumors, has targeting property, and can be used for treating various solid tumors. The VV [delta] TK [delta] C2L-LO uses an LO gene as a therapeutic gene, and the vector can selectively kill tumor cells, has tumor targeting and anti-tumor effects, lays a foundation for clinical application of tumor targeting gene engineering drugs, and provides an effective new method for tumor treatment.
Owner:ZHENGZHOU UNIV

Primer set, composition and kit for detecting vaccinia virus and analysis method using same

PendingUS20260176706A1Microbiological testing/measurementCowpox virusVaccinia
The present invention relates to a primer set, composition, kit for the detection of vaccinia virus for the detection and quantification of vaccinia virus and an analysis method using the same, and the primer set for the detection of vaccinia virus has a shorter analysis period and superior sensitivity and specificity compared to the conventional virus quantitation method, so that when real-time PCR applied to such a primer set is performed, it is possible to detect and quantify vaccinia virus more quickly and accurately in real time.
Owner:KOLON INDUSTRIES INC

Martin inhibitor and application thereof in preparation of anti-tumor drugs

The invention relates to the technical field of biomedical engineering. The invention provides an application of an oncolytic vaccinia virus carrying a stritin interference sequence in an anti-tumor drug, a stritin inhibitor recombinant vector, an application of the stritin inhibitor recombinant vector in preparation of the anti-tumor drug, and an anti-tumor drug composition taking a stritin inhibitor or the stritin inhibitor recombinant vector as an active component. According to the present invention, the inhibition on the Stritin can be used for preparing the anti-tumor virus drug, and particularly the recombinant vector is formed by recombining the Stritin inhibitor and the vaccinia virus, such that the advantages of the Stritin inhibitor and the vaccinia virus can be combined, the new target spot is provided for the tumor virus treatment, and the broad clinical application prospect is provided.
Owner:HANGZHOU GONGCHU BIOTECH CO LTD

Compositions and methods for preventing or treating hepatitis c viral infections

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.
Owner:EMORY UNIVERSITY

Inhibitors of striatin-interacting proteins and their use in the preparation of anti-tumor drugs

ActiveCN109453392Binhibitory response levellower response levelUnknown materialsDsDNA virusesPharmaceutical drugVaccinia
The present invention relates to the field of biomedical engineering technology, and provides the use of a striae-interacting protein (STRIP) inhibitor in the preparation of an anti-tumor drug, a striae-interacting protein inhibitor recombinant vector and its use in the preparation of an anti-tumor drug, and an anti-tumor drug composition with a striae-interacting protein inhibitor or a striae-interacting protein inhibitor recombinant vector as an active component. The present invention can be used to prepare an anti-tumor viral drug by inhibiting STRIP, especially by recombining it with vaccinia virus into a recombinant vector, which can combine the advantages of STRIP inhibitors and vaccinia virus, provide a new target for viral treatment of tumors, and has broad clinical application prospects.
Owner:HANGZHOU GONGCHU BIOTECH CO LTD

Vaccinia virus that induces cell fusion and use thereof

This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.
Owner:TOTTORI UNIVERSITY

Use of extract from rabbit skin inflamed by vaccinia virus in treating parkinson's disease

PendingUS20250213622A1Nervous disorderUnknown materialsCowpox virusVaccinia
The use of extract from rabbit skin inflamed by vaccinia virus for treating Parkinson's disease or restoring neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Parkinson's disease is provided. The extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Owner:STAR BRIGHT BIO-TECH LTD

ONCOLYTIC VACCINE VIRUS

UndeterminedCY1126239T1Vaccine virusVaccinia
The present invention relates to an oncolytic vaccinia virus and viral vectors for use in the treatment of cancer wherein the virus consists of at least three vaccinia virus promoters positioned in the same orientation.
Owner:QUEEN MARY UNIV OF LONDON

Compositions comprising an oncolytic virus and a glial cell for use in treating neuroblastoma

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.
Owner:IMMUNOLUX INT CORP

Enzymatic RNA Capping Method

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.
Owner:NEW ENGLAND BIOLABS INC

A recombinant construct, a recombinant oncolytic virus and methods of construction and use thereof

This invention relates to the fields of biotechnology and targeted therapy, specifically to a recombinant construct, a recombinant oncolytic virus, its construction method, and its applications. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes for CD16 and CD19 into the genome of an oncolytic vaccinia virus. The antibodies secreted by this recombinant virus can not only bridge NK cells and CD19-positive B-cell lymphoma cells, increasing the contact between NK cells and tumor cells and their accumulation within tumor tissue, but also synergize with the tumor-lysing effect of the oncolytic virus, breaking down the stromal barrier, reshaping the tumor microenvironment, and enhancing therapeutic efficacy.
Owner:HANGZHOU FIRST PEOPLES HOSPITAL

Compositions and methods for immunodominant antigens

PCT designated stage expiredWO2008140478A8Antibacterial agentsVirus peptidesDiseaseBorrelia sp
Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.
Owner:IMMPORT THERAPEUTICS +3

Use of extract from rabbit skin inflamed by vaccinia virus in treatment of alzheimer's disease

The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Owner:ZODIAC BIO TECH LTD

Pharmaceutical composition for treating cancer comprising vaccinia virus and hydroxyurea as active ingredients

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention, exhibits a higher anti-cancer effect and safety than conventional vaccinia virus alone administration. Therefore, the pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention can be advantageously used for treating cancer.
Owner:BAYER KNOX GMBH

Recombinant modified saRNA (VRP) and vaccinia virus Ankara (MVA) prime-boost regimen

The present invention provides compositions, vaccines, and methods for inducing protective immunity to immunogens in humans. Protective immune responses are obtained by using saRNA, particularly VRP vectors as a prime and MVA vectors for boosting. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors that contain at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus (e.g., EBV).
Owner:BAVARIAN NORDIC AS

Compositions and methods for preventing or treating hepatitis c viral infections

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.
Owner:EMORY UNIVERSITY

Enzymatic RNA capping method

To provide a method for efficiently capping RNA in vitro.SOLUTION: In some embodiments, the capping reaction can be done at high temperature using Vaccinia capping enzyme or variants thereof. In other embodiments, the capping reaction may comprise capping enzymes from amoebic large viruses, such as Faust, Mimivirus, or Moumouvirus, or variants thereof. Compositions and kits for practicing the methods are also provided.SELECTED DRAWING: None
Owner:NEW ENGLAND BIOLABS INC

Preparation and clinical application of growth differentiation factor 11 (GDF11) mRNA for promoting wound healing

The invention belongs to the field of clinical technology, and provides preparation and clinical application of growth differentiation factor 11 (GDF11) mRNA for promoting wound healing, and the preparation method comprises the following steps: S1, carrying out N1 psi modification on GDF11 mRNA, and replacing uracil in an original sequence with N1 psi; s2, synthesizing the modified GDF11 mRNA (messenger Ribonucleic Acid); s3, purifying the synthesized GDF11 mRNA (messenger Ribonucleic Acid), so as to obtain mRNA with modified nucleoside; by optimizing the preparation method of growth differentiation factor 11 (GDF11) mRNA, the preparation method comprises the following steps: performing N1 psi modification, synthesizing by adopting a vaccinia enzyme m capping 7G capping system, adding a poly (A) tail, purifying, and wrapping in lipid nanoparticles (LNP) to form a stable delivery system, so that the stability and translation efficiency of mRNA are remarkably improved, and the stability and translation efficiency of the GDF11 are remarkably improved. And the defects existing in treatment by directly using the GDF11 protein in the prior art are overcome, an efficient and safe new strategy is provided for diabetes wound treatment, and remarkable beneficial effects are achieved.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV

Enzymatic RNA Capping Method

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.
Owner:NEW ENGLAND BIOLABS INC

Construction method and application of A41L gene deleted oncolytic vaccinia virus vector

The invention relates to a novel oncolytic vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-RFP and VVL [delta] TK [delta] N1L [delta] A41L-IL-27 with deletion of A41L genes and an application of the novel oncolytic vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-IL-27. The novel oncolytic vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-RFP is a vaccinia virus Lister strain, a TK gene, an N1L gene and an A41L gene are deleted at a fixed point, and the vector has tumor targeting, can carry an exogenous therapeutic gene, and is used for treating various solid tumors. The vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-IL-27 can kill tumor cells and express interleukin 27 at the same time, and the vaccinia virus vector VVL [delta] TK [delta] N1L [delta] A41L-IL-27 and the oncolytic vaccinia virus have a stronger anti-tumor effect. The virus vectors VVL [delta] TK [delta] N1L [delta] A41L-RFP and VVL [delta] TK [delta] N1L [delta] A41L-IL-27 provided by the invention can be used as a potential novel gene therapy drug for treating pancreatic cancer, colon cancer, lung cancer and other tumors.
Owner:ZHENGZHOU UNIV